Dienstag 26. März 2019

TWINCORE / SFB 900-Seminar

Justin Bailey, MD, PhD

Associate Professor of Medicine, Johns Hopkins University School of Medicine; Baltimore, Maryland

Titel: Can broadly neutralizing antibodies lead us to an HCV vaccine?

Zeit: 17:00 Uhr s.t.,
Ort: TWINCORE Seminar room 0.02

Ansprechpartner: Prof. Thomas Pietschmann


Hepatitis C virus (HCV) infects over 71 million people worldwide and kills more people in the United States annually than HIV. Direct-acting antiviral (DAA) therapy has revolutionized care, but development of a vaccine for HCV remains essential for disease eradication. The enormous genetic diversity of HCV makes this a daunting challenge. Early development of broadly-neutralizing antibodies is associated with spontaneous clearance of HCV infection, but the mechanisms of immune-mediated clearance are poorly defined. We have isolated broadly neutralizing monoclonal antibodies (bNAbs) from individuals who cleared HCV infection, and studied how these antibodies can drive viral evolution, leading to a loss of replicative fitness. We are also studying the structural interactions between these bNAbs and HCV envelope proteins to identify conserved binding epitopes and antibody features critical for neutralizing breadth, with the goal of informing HCV vaccine development.

About Justin Bailey

Dr. Bailey is an Associate Professor of Medicine and an Infectious Diseases physician at the Johns Hopkins University School of Medicine in Baltimore, Maryland. He earned his M.D. and Ph.D. degrees from Johns Hopkins and completed medical residency training at Massachusetts General Hospital in Boston, Massachusetts. His laboratory focuses on virus-host interactions, with a particular focus on broadly neutralizing antibodies against hepatitis C virus (HCV).

Kinchen VJ, Zahid MN, Flyak AI, Soliman MG, Learn GH, Wang S, Davidson E, Doranz BJ, Ray SC, Cox AL, Crowe JE Jr, Bjorkman PJ, Shaw GM, Bailey JR. Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. Cell Host Microbe. 2018 Nov 14;24(5):717-730.e5.

Flyak AI, Ruiz S, Colbert MD, Luong T, Crowe JE Jr, Bailey JR, Bjorkman PJ. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. Cell Host Microbe. 2018 Nov 14;24(5):703-716.e3.

Mankowski MC, Kinchen VJ, Wasilewski LN, Flyak AI, Ray SC, Crowe JE Jr, Bailey JR. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proc Natl Acad Sci U S A. 2018 Jan 2;115(1):E82-E91.